Osimertinib Recruiting Phase 2 Trials for Prostate Cancer / Cervical Carcinoma / Gliomas / Recurrent Colorectal Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Breast Carcinoma / Refractory Malignant Solid Neoplasm / Recurrent Uterine Corpus Carcinoma / Recurrent Malignant Solid Neoplasm / Gastric Carcinoma / Recurrent Bladder Carcinoma / Ovarian Carcinoma / Lung, Carcinoma / Recurrent Skin Carcinoma / Recurrent Colon Carcinoma / Oesophageal Carcinoma / Refractory Plasma Cell Myeloma / Recurrent Liver Carcinoma / Recurrent Esophageal Carcinoma / Refractory Lymphomas / Head and Neck Carcinoma / Carcinoma, Colorectal / Recurrent Thyroid Gland Carcinoma / Recurrent Plasma Cell Myeloma / Endometrial Carcinoma / Recurrent Melanoma / Recurrent Head and Neck Carcinoma / Carcinoma, Pancreatic / Recurrent Lymphoma / Uterine Corpus Cancer / Plasma Cell Myeloma / Recurrent Solid Neoplasm / Recurrent Rectal Carcinoma / Thyroid Gland Carcinoma / Rectal Carcinoma / Carcinoma, Breast / Liver and Intrahepatic Bile Duct Carcinoma / Refractory Malignant Neoplasm / Advanced Malignant Solid Neoplasm / Recurrent Gliomas / Recurrent Pancreatic Carcinoma / Recurrent Cervical Carcinoma / Renal Carcinoma / Colon Carcinoma / Recurrent Prostate Carcinoma / Bladder Carcinoma / Malignant Uterine Neoplasm / Skin Carcinoma / Recurrent Lung Carcinoma / Solid Neoplasms / Advanced Malignant Neoplasm / Melanoma / Malignant Lymphomas / Recurrent Gastric Carcinoma Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02465060Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)